$$ IVOICE INC $$
Seite 1 von 2 Neuester Beitrag: 01.04.08 17:23 | ||||
| Eröffnet am: | 26.10.06 12:19 | von: carpediem7 | Anzahl Beiträge: | 42 |
| Neuester Beitrag: | 01.04.08 17:23 | von: 0815ax | Leser gesamt: | 6.282 |
| Forum: | Hot-Stocks | Leser heute: | 6 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
und verkaufen wenn ...
habe heute für 0,03 nachgekauft und mal kurz meinen Einstiegskurs halbiert...
Kurs USA 0,061$ PariKurs 0,0488€
Berlin heute 0,03€
über 30% unter Pari...
MATAWAN, N.J.--(BUSINESS WIRE)--June 15, 2006--Thomas Pharmaceuticals Ltd, a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that it will present to senior industry executives at the National Association of Chain Drug Stores\' (NACDS) Annual Marketplace Conference scheduled from June 23-27th in San Diego. Thomas Pharmaceuticals will be showcasing the launch of the New Black Cherry flavor of Acid + All(TM) and unveiling two new product lines targeted at today\'s affluent baby boomer market. The presentation will include a sleekly packaged, high-end antacid tablet, Acid + All(TM) , which is changing the over-the-counter pharmaceutical category by offering a highly effective pharmaceutical product within an attractive packaging. Consumers are now able to find Acid + All(TM)\'s chic blue and white tin at their local drugstores.
NACDS is the industry\'s largest trade show attended by 200 retailers, representing 100,000 stores and $540 billion in buying power. At the conference, Thomas\' management will meet with senior executives and division and category managers responsible for bringing new products to drugstore customers. "This is a tremendous opportunity to present Acid + All(TM), the first product in the Thomas Pharmaceuticals Ltd. family of innovative over the counter healthcare products to decision makers and to begin the purchase order process," said Mr. Thomas, President and Founder of Thomas Pharmaceuticals Ltd.
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceutical plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
About Thomas Pharmaceuticals Ltd:
Thomas Pharmaceuticals Ltd., based in New York, NY, develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company\'s shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act" provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management\'s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on iVoice, please visit http://www.ivoice.com or http://www.thomaspharmaceuticals.com/
CONTACT: iVoice, Inc.
Investor Relations
Dolores Serafin, 732-441-7700
investors@ivoice.comhttp://www.ivoice.com
or
CEOcast, Inc. for iVoice
Andrew Hellman, 212-732-4300
adhellman@ceocast.com
SOURCE: iVoice, Inc.
iVoice, Inc., Announces 1-for-200 Reverse Stock Split and Change of Trading Symbol to IVOI
Wednesday April 26, 4:30 pm ET
MATAWAN, N.J.--(BUSINESS WIRE)--April 26, 2006--iVoice, Inc (OTCBB:IVOC - News), announced today that its common stock will split 1-for-200. Each 200 shares of common stock will be converted into one new share of common stock. Shareholders of iVoice may retain their present certificates and do not have to submit them for replacement.
The new trading symbol of iVoice, Inc. will be: IVOI
The shareholders of iVoice, Inc. approved this reverse split at the Company\'s Annual Meeting of Shareholders that was held on March 31, 2006.
The shareholders of iVoice also approved the following proposals:
1. The grant of discretionary authority for the Board of Directors to
declare a cash dividend to Class A Common Stock shareholders of
$1.5 million.
2. The grant of discretionary authority for the Board of Directors to
effect the repurchase of sixty percent (60%) of the issued and
outstanding Class B Common Stock shares for $1.5 million.
3. The re-authorization of 10 billion of Class A Common Stock.
4. The grant of discretionary authority for the Board of Directors to
effect the buyback by the Company of up to $1 million of the Class
A Common Stock.
7. The re-election of two members of the Board of Directors: Jerome
Mahoney and Frank Esser
8. Approval of the iVoice, Inc. 2005 Stock Incentive Plan.
9. The ratification our Board of Directors\' selection of Bagell
Josephs Levine & Company, LCC to audit our financial statements
for the fiscal year ending December 31, 2005.
10. The grant of discretionary authority for the Board of Directors to
file an amendment to our Certificate of Incorporation to change
our name to ARX Emerge, Inc.
About iVoice, Inc.
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the Company\'s shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may offer long term growth prospects to increase shareholder value. For more information, contact CEO Jerry Mahoney at (732) 441 7700 or by e-mail at jerrym@ivoice.com.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act" provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management\'s good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Factors that could cause or contribute to such differences include, but are not limited to those risk factors that are set forth in the section entitled "Forward Looking Statements - Cautionary Factors" in the Company\'s Form 10-KSB for fiscal year ended December 31, 2005 and other filings with the Securities and Exchange Commission from time to time. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on iVoice, please visit http://www.ivoice.com
heute wieder welche zu 0,035...
könnt mir gerne noch mehr "verkaufen"...
habe noch Order zu 0,03 drin... für alle Frustrierten...
bin ja großzügig...
Optionen
| Boardmail an "RockeFäller" |
Wertpapier: iVoice Inc |
darum geht es doch gar nicht...
ich finde es nur nett, das hier alle ihre Aktien wegschmeißen...nur um die roten Zahlen aus ihrer
Depotübersicht zu bekommen...und das zu über 30% unter Pari...
und falls die Aktie irgendwann mal wieder steigt...
und auch wenn das in 10Jahren ist...dann heulen wieder alle...
iVoice's Thomas Pharmaceuticals Ltd. Announced Acid + All(TM) Antacid Table Product Line Now in More Than 20,000 Drug Stores Nationwide
Anzeige:
www.kleinspekulant.com: Strategie eines Kleinspekulanten und
meine besten Aktien um die Profis zu schlagen. Erfahren Sie mehr...
"We are pleased that in a short period of time that Acid + All(TM) has enjoyed such success from leading drugstore chains and pharmacies across the country that more than 20,000 of them have elected to carry the product," said Tom Thomas, President and Founder of Thomas Pharmaceuticals. "Despite the rapid adoption of the product, in the coming months we plan to further increase distribution by expanding relationships with drugstore chains such as Rite Aid Corporation and other leading retailers."
Acid + All(TM), the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid + All(TM) will be available in a sleek, 32-count pillbox and will retail for approximately $3.89. Thomas Pharmaceuticals plans to introduce Acid + All(TM) line extensions later this year along with other new over-the-counter products. For more information about Acid + All(TM) go to www.acidall.com.
About Thomas Pharmaceuticals
Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid + All(TM), is a calcium-enriched, sugar free, anti-gas antacid. On August 9, 2006, iVoice, Inc. entered into a Stock Purchase Agreement dated August 7, 2006 by and among Thomas Pharmaceuticals Ltd.,Thomas Pharmaceutical Acquisition Corp. ("Thomas Acquisition") and iVoice, Inc. whereby Thomas Acquisition has agreed to purchase all of the outstanding securities presently held by iVoice. iVoice may terminate this Stock Purchase Agreement should the closing not have ocurred by October 31, 2006. Thomas Acquisition is substantially controlled by the original founders and management of Thomas Pharmaceuticals.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on iVoice, please visit http://www.ivoice.com or http://www.thomaspharmaceuticals.com/.
sehr hoher Umsatz...
vielleicht kommt ja langsam Bewegung rein...
;-))
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
IVOI 0.0073 0.0059
Today 5d 1m 3m 1y 5y 10y
iVoice, Inc., Announces Record Date for Spin-Off of Thomas Pharmaceuticals Ltd. To Shareholders
Fifth Spin-Off and Fifth Stock Dividend to the Shareholders
iVoice, Inc. (OTC Bulletin Board: IVOI), announced today the record date of October 15, 2007 for the pending spin-off in the form of a special dividend of its wholly owned subsidiary, Thomas Pharmaceuticals Ltd. (“Thomas Pharmaceuticals”).
Each iVoice shareholder as of the record as of October 15, 2007 will receive shares of Thomas Pharmaceuticals subject to: (i) the record having passed, (ii) the Securities and Exchange Commission reviewing and approving the final amendment to the Thomas Pharmaceuticals’ Form SB-2/A and (iii) declaration of effectiveness of this registration statement by the Securities and Exchange Commission. In order to receive shares in Thomas Pharmaceuticals, you must own shares of iVoice, Inc. on the record date of October 15, 2007. It is anticipated that the distribution in the form of a special dividend of Thomas Pharmaceuticals shares will occur sometime in November 2007. Following the distribution, Thomas Pharmaceuticals plans to have its shares traded on the NASD OTC Bulletin Board.
About iVoice, Inc:
iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the Company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.
Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
For more information on iVoice, please visit http://www.ivoice.com
Ist ne heisse Sache - Jedenfalls geht es um Dividende ( spin off ).
Man bekommt Aktien von einer Tochterfirma wenn man am
15. October (record date) Aktien von IVOICE hat.
Hier müssten nun noch neue Infos kommen zu dem spin off.
Halt noch einiges nach oben drin aber heiss ;-)
Trage mich mit dem Gedanken, diese Aktie in mein Depot zu legen.
Hat jemand weitere Hintergrundinformationen?...
ciao ax
VK 766.666 (zu 0.004) => dadurch Tagesendkurs 0.003
Gewinnmitnahme (0.003 nach 0.004 zu 0.003) oder tendenzielle Entwicklung wieder gen 0.001 ???
Tifflor - wie siehst du es ?...
ciao ax